News Search Results
Aug 08, 2025, 10:16 ET Leather for Automotive Seats Market to Surpass USD 69.1 Billion by 2031, Driven by Soaring Demand for Luxury and Electric Vehicles, According to New Report by The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 08, 2025, 10:01 ET Transparent Ceramics Market to Reach USD 768.03 Million by 2031, Driven by Demand from Defense, Electronics, and Optics Sectors | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 08, 2025, 09:15 ET Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr. Robert Wenham, Chair of the Gynecologic
More news about: Anixa Biosciences, Inc.
Aug 08, 2025, 09:05 ET Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
$ 24,850 About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line
More news about: Oncolytics Biotech® Inc.
Aug 08, 2025, 09:00 ET Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
not required under Section 720(b) of the TSX Company Manual. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line
More news about: Oncolytics Biotech® Inc.
Aug 08, 2025, 08:30 ET GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology
regions At a time when biotechnology is advancing faster than ever—and trust, transparency, and precision are in high demand—GenScript's brand elevation is a confident signal to scientists, investors, and stakeholders worldwide. The future of biotechnology is not written yet. GenScript
More news about: GenScript Biotech Corporation
Aug 08, 2025, 07:45 ET Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company's financial flexibility, reduce
More news about: Heron Therapeutics, Inc.
Aug 08, 2025, 07:45 ET Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2025 and recent corporate updates.
More news about: Heron Therapeutics, Inc.
Aug 08, 2025, 06:00 ET Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of second quarter 2025 financial results and subsequent conference call. The Company
More news about: Heron Therapeutics, Inc.
Aug 07, 2025, 16:15 ET Nektar Therapeutics Reports Second Quarter 2025 Financial Results
information and a PIN allowing them to access the live call. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Aug 07, 2025, 16:06 ET Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug. 7, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Aug 07, 2025, 12:00 ET Brain Navi Biotechnology's NaoTrac performs first surgeries in Spain
https://www.prnewswire.com/news-releases/brain-navi-biotechnologys-naotrac-performs-first-surgeries-in-spain-302523889.html SOURCE Brain Navi Biotechnology Co., Ltd.
More news about: Brain Navi Biotechnology Co., Ltd.
Aug 07, 2025, 11:27 ET Global Momentum in Wastewater Treatment Sparks New Opportunities for Innovation | BCC Research LLC
Rest of the World. Key segments include polymeric and ceramic materials, membrane formats like hollow fiber and spiral wound, and applications in biotechnology, pharmaceuticals, potable water, wastewater, and food and beverages. Market size is assessed in terms of both value and volume. Purchase
More news about: BCC Research LLC
Aug 07, 2025, 10:15 ET Brain Computer Interface Market to Soar from USD 1.6 Billion in 2024 to USD 6.3 Billion by 2033, at 20.5% CAGR - Market Research Intellect
Stem Cell Research, Drug Development, Clinical Diagnostics, Toxicology) and End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Clinical Laboratories, Contract Research Organizations, Diagnostic Laboratories) and geographical regions
More news about: Market Research Intellect
Aug 07, 2025, 10:01 ET Update Hydrolyzed Collagen Market Forecast at CAGR 5.5% Through 2031: Highlight Rising Demand for Functional Foods and Collagen Supplements | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 07, 2025, 10:00 ET NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LACRIFILL® CANALICULAR GEL INCLUSION IN NEW DRY EYE WORKSHOP (DEWS) III MANAGEMENT AND THERAPY REPORT FROM THE TEAR FILM AND OCULAR SURFACE SOCIETY (TFOS) IN AMERICAN JOURNAL OF OPHTHALMOLOGY
Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace. Safe HarborThis press
More news about: Nordic Pharma
Aug 07, 2025, 10:00 ET NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LACRIFILL® CANALICULAR GEL INCLUSION IN NEW DRY EYE WORKSHOP (DEWS) III MANAGEMENT AND THERAPY REPORT FROM THE TEAR FILM AND OCULAR SURFACE SOCIETY (TFOS) IN AMERICAN JOURNAL OF OPHTHALMOLOGY
Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace. Safe HarborThis press
More news about: Nordic Pharma
Aug 07, 2025, 08:31 ET MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the second quarter ended June
More news about: MetaVia Inc.
Aug 07, 2025, 08:00 ET K36 Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for KTX-2001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Announces Clinical Trial Collaboration with Bayer for Supply of Darolutamide
Aug. 7, 2025 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel, targeted therapies for cancers with unmet medical need, today announced the US Food and Drug Administration (FDA) has
More news about: K36 Therapeutics
Aug 07, 2025, 07:30 ET Switch Bioworks Expands Leadership Team and Moves into New Facility to Accelerate Development of its Microbial Fertilizer Products
SAN FRANCISCO, Aug. 7, 2025 /PRNewswire/ -- Switch Bioworks, a biotechnology company developing low-cost and sustainable fertilizers, announced today the addition of two senior leaders to its executive team and a move into
More news about: Switch Bioworks
Aug 07, 2025, 07:28 ET ARTBIO Appoints Four New Board Members, Co-Founder Transitions to Technical Advisory Board Role
most recently served as Head of Equity Capital Markets in the Americas. While at Goldman Sachs, Mr. Gelman advised on and led many high-profile biotechnology financings. Mr. Gelman holds a B.S.E. in Industrial Engineering from the University of Michigan."Following
More news about: ARTBIO
Aug 07, 2025, 07:05 ET REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Aug 07, 2025, 07:00 ET REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
treatment or retinal laser; surgical treatment may be required for advanced PDR.2 ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Aug 07, 2025, 06:45 ET Lilly reports second-quarter 2025 financial results and raises guidance
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Aug 07, 2025, 06:30 ET Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.